Literature DB >> 22302756

Developing microRNA therapeutics.

Eva van Rooij1, Angela L Purcell, Arthur A Levin.   

Abstract

Rarely a new research area has gotten such an overwhelming amount of attention as have microRNAs. Although several basic questions regarding their biological principles still remain to be answered, many specific characteristics of microRNAs in combination with compelling therapeutic efficacy data and a clear involvement in human disease have triggered the biotechnology community to start exploring the possibilities of viewing microRNAs as therapeutic entities. This review serves to provide some general insight into some of the current microRNAs targets, how one goes from the initial bench discovery to actually developing a therapeutically useful modality, and will briefly summarize the current patent landscape and the companies that have started to explore microRNAs as the next drug target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302756     DOI: 10.1161/CIRCRESAHA.111.247916

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  214 in total

1.  Taming endothelial activation with a microRNA.

Authors:  Jason E Fish; Myron I Cybulsky
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

2.  Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.

Authors:  Amaryllis H Van Craenenbroeck; Kristien J Ledeganck; Katrijn Van Ackeren; Angelika Jürgens; Vicky Y Hoymans; Erik Fransen; Volker Adams; Benedicte Y De Winter; Gert A Verpooten; Christiaan J Vrints; Marie M Couttenye; Emeline M Van Craenenbroeck
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

3.  High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro.

Authors:  Fan Wang; Jeremy T-H Chang; Chester Jingshiu Kao; R Stephanie Huang
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

Review 4.  MicroRNA control of vascular endothelial growth factor signaling output during vascular development.

Authors:  Lan T H Dang; Nathan D Lawson; Jason E Fish
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

Review 5.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

Review 6.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

Review 7.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

8.  A systematic evaluation of microRNAs in regulating human hepatic CYP2E1.

Authors:  Yong Wang; Dianke Yu; William H Tolleson; Li-Rong Yu; Bridgett Green; Linjuan Zeng; Yinting Chen; Si Chen; Zhen Ren; Lei Guo; Weida Tong; Huaijin Guan; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2017-04-22       Impact factor: 5.858

9.  The comparison of miRNAs that respond to anti-breast cancer drugs and usnic acid for the treatment of breast cancer.

Authors:  Demet Cansaran-Duman; Ümmügülsüm Tanman; Sevcan Yangın; Orhan Atakol
Journal:  Cytotechnology       Date:  2020-10-30       Impact factor: 2.058

10.  MicroRNA regulation of nonmuscle myosin light chain kinase expression in human lung endothelium.

Authors:  Djanybek M Adyshev; Nurgul Moldobaeva; Brandon Mapes; Venkate Elangovan; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.